At LabGenius Therapeutics (LabGenius), our mission is to discover the next generation of therapeutic antibodies by combining human and machine intelligence. To do this, we’ve pioneered the development of EVA™, state-of-the-art automated platform, enabling the closed-loop discovery of high-performing, non-intuitive antibody designs using proprietary, ML-grade datasets. For our wholly-owned therapeutic pipeline, we’re using our closed-loop discovery engine to establish a pipeline of highly selective T-cell engagers and ADCs for the treatment of solid tumours.

LabGenius has raised >£55M and is backed by top-tier investors, including M Ventures, Octopus Ventures, LG Corp, Atomico, Kindred Capital, Lux Capital and Obvious Ventures amongst others. The company is headquartered in London (UK) where we’ve established a cutting-edge antibody engineering facility. The company is staffed by a multidisciplinary team of more than 50 scientists and engineers.

You’ll be a pivotal member ...